{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:49:56Z","timestamp":1778132996631,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T00:00:00Z","timestamp":1367280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) are a class of medications indicated for the treatment of gastric acid\u2013related diseases. Hypomagnesemia is a rare but serious adverse effect of PPIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To address the association between the use of different PPIs and hypomagnesemia by examining the frequency of occurrence of hypomagnesemia among the reported adverse drug reactions from the Food and Drug Administration (FDA) Adverse Event Reporting System database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      We conducted a cross-sectional study of PPI-associated adverse effect cases reported to the FDA between November 1, 1997, and April 1, 2012. Logistic regression was used to examine the association of sex, age, and different PPIs with hypomagnesemia. \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      Analysis was conducted to investigate the association of PPI-associated hypomagnesemia with hypocalcemia and hypokalemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Among 66,102 subjects identified as experiencing 1 or more adverse effects while taking a PPI, 1.0% (n = 693) were reported to have hypomagnesemia. The mean (SD) age of PPI users presenting with hypomagnesemia was 64.4 (12.9) years. Results from logistic regression indicated that, compared with esomeprazole, all other PPIs had a higher rate of hypomagnesemia, with pantoprazole having the highest rate (OR 4.3; 95% CI 3.3\u20135.7; p &lt; 0.001). The risk of female subjects having hypomagnesemia (OR 0.83; 95% CI 0.71\u20130.97; p = 0.016) was significantly lower than that of males. Elderly subjects (age &gt;65 years) were at increased risk of PPI-associated hypomagnesemia (OR 1.5; 95% CI 1.2\u20131.7; p &lt; 0.001). \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      Analysis showed strong association between hypomagnesemia and both hypocalcemia (p &lt; 0.001) and hypokalemia (p &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>All PPIs were associated with hypomagnesemia, with esomeprazole having the lowest risk and pantoprazole having the highest risk. The risk of PPI-associated hypomagnesemia was higher in males and the elderly population. Hypocalcemia and hypokalemia commonly coexisted with PPI-associated hypomagnesemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1r556","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T09:10:41Z","timestamp":1367399441000},"page":"773-780","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":71,"title":["Proton Pump Inhibitor\u2013Associated Hypomagnesemia: What Do FDA Data Tell Us?"],"prefix":"10.1177","volume":"47","author":[{"given":"Chee Phun","family":"Luk","sequence":"first","affiliation":[{"name":"Chee Phun Luk MPharm, Pharmacist, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Parsons","sequence":"additional","affiliation":[{"name":"Richard Parsons PhD, Senior Lecturer, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya Ping","family":"Lee","sequence":"additional","affiliation":[{"name":"Ya Ping Lee PhD, Lecturer, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery David","family":"Hughes","sequence":"additional","affiliation":[{"name":"Jeffery David Hughes PhD, Head of School, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,4,30]]},"reference":[{"key":"bibr1-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0538-y"},{"key":"bibr2-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2008.09.016"},{"key":"bibr3-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2009.03.014"},{"key":"bibr4-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-010-0141-0"},{"key":"bibr5-aph.1R556","unstructured":"Commonwealth Government of Australia. Drug Utilisation Subcommittee (DUSc) database. www.australianprescriber.com\/magazine\/34\/6\/artid\/1063 (accessed 2012 Apr 9)."},{"key":"bibr6-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2009.11.004"},{"key":"bibr7-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1560-3"},{"key":"bibr8-aph.1R556","doi-asserted-by":"publisher","DOI":"10.2165\/11599320-000000000-00000"},{"key":"bibr9-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.023"},{"key":"bibr10-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32833ff5d6"},{"key":"bibr11-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc066308"},{"key":"bibr12-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39505.738981.BE"},{"key":"bibr13-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03194.x"},{"key":"bibr14-aph.1R556","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ando.2008.03.003","volume":"69","author":"Francois M","year":"2008","journal-title":"[French] Annales d Endocrinologie"},{"key":"bibr15-aph.1R556","first-page":"P24","volume":"15","author":"Agarwal N","year":"2008","journal-title":"Endocrine Abstracts"},{"key":"bibr16-aph.1R556","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-10-200911170-00016"},{"key":"bibr17-aph.1R556","first-page":"169","volume":"67","author":"Kuipers MT","year":"2009","journal-title":"Neth J Med"},{"key":"bibr18-aph.1R556","first-page":"P50","volume":"16","author":"Druce MR","year":"2009","journal-title":"Endocrine Abstracts"},{"key":"bibr19-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.11.019"},{"key":"bibr20-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.03.013"},{"key":"bibr21-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq021"},{"key":"bibr22-aph.1R556","first-page":"329","volume":"68","author":"Fernandez-Fernandez FJ","year":"2010","journal-title":"Neth J Med"},{"key":"bibr23-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5087"},{"key":"bibr24-aph.1R556","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.11-6-591"},{"key":"bibr25-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.199"},{"key":"bibr26-aph.1R556","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-6-201109200-00022"},{"key":"bibr27-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04092.x"},{"key":"bibr28-aph.1R556","doi-asserted-by":"publisher","DOI":"10.2174\/157488611797579320"},{"key":"bibr29-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2011.03.007"},{"key":"bibr30-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01509.x"},{"key":"bibr31-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.07.2009.2098"},{"key":"bibr32-aph.1R556","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.7748"},{"key":"bibr33-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2011.11.011"},{"key":"bibr34-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182333820"},{"key":"bibr35-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03808.x"},{"key":"bibr36-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3224"},{"key":"bibr37-aph.1R556","unstructured":"Food and Drug Administration. FDA drug associated with long-term use of proton pump inhibitor drugs. www.fda\/gov\/Drugs\/DrugSafety\/ucm245011.htm (accessed 2012 Apr 9)."},{"key":"bibr38-aph.1R556","unstructured":"Therapeutic Goods Administration. Medicines safety update. www.tga.gov.au\/hp\/msu-2011-03.htm (accessed 2012 Apr 9)."},{"key":"bibr39-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1042\/CS20120045"},{"key":"bibr40-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"bibr41-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-199803000-00006"},{"key":"bibr42-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2008.12.001"},{"key":"bibr43-aph.1R556","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2007.060"},{"key":"bibr44-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/61.15.1569"},{"key":"bibr45-aph.1R556","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4877"},{"key":"bibr46-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1053\/bega.2000.0197"},{"key":"bibr47-aph.1R556","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i12.1574"},{"key":"bibr48-aph.1R556","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03824.x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1R556","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:54Z","timestamp":1777374774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,30]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1345\/aph.1R556"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r556","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,30]]}}}